CellCentric (Series C)
Funding Details
- Awarder
- RSS - techfundingnews.com
- Date Award
- May 20, 2025
- Vertical
- Biotech
- Funding URL
- View Funding Page
- Funding Amount:
- $120,000,000
Company Info
- Traction
- CellCentric plans to launch a Phase II/III clinical trial targeting heavily pretreated multiple myeloma patients and has received Fast Track and orphan drug designations from the FDA.
- Founders
- Azim Surani
- Company Description
- CellCentric is a clinical-stage biotech company focused on developing a novel oral cancer drug, inobrodib, which targets multiple myeloma with a unique mechanism of action and a strong safety profile.
- Market
- Cancer treatment
- Location
- UK
- Coinvestors
- RA Capital Management, Forbion, Avego Bioscience Capital, BrightEdge